Gefapixant Citrate

Adults: Gefapixant should be started and monitored by doctors who have experience in managing patients with chronic cough disorders. Adult patients: the dose is one 45 mg tablet by mouth twice daily, with or without food. Patients should be told that if they miss a dose, they should skip it and take the next dose at the usual time. Use in elderly patients: no dose adjustment of Gefapixant is needed because of age, and no age-specific differences in its efficacy or safety have been established. The medicine is mainly cleared by the kidneys. Older patients are more likely to have impaired kidney function, so the risk of adverse effects may be higher in them. Caution should be taken with the initial dosing frequency. Use in the pediatric population: the safety and efficacy of Gefapixant have not been established in patients below 18 years of age. Obstructive sleep apnea: Gefapixant should not be used in patients with refractory chronic cough or unexplained chronic cough who also have obstructive sleep apnoea. Patients with liver disease: Gefapixant has not been studied in patients with hepatic impairment. Patients with renal impairment: for patients with severe renal impairment (eGFR<30 ml/minute/1.73 m2) who are not on dialysis, the recommended dose of Gefapixant is one 45 mg tablet once daily, with or without food. No dose adjustment is needed in patients with mild or moderate renal impairment (eGFR >30 ml/minute/1.73 m2). In patients with severe renal impairment (eGFR <30 ml/minute/1.73 m2) who do not need dialysis, the dose of Gefapixant should be adjusted. Effect on driving ability and on the use of machines: patients may feel dizzy after using Gefapixant, and this may affect their ability to drive and use machines.